摘要 |
<p>Provided are substituted diaminocarboxamide pyrimidine compounds, of general formula (I), and substituted diaminocarbonitrile pyrimidine compounds, of general formula (IB), where the variables are as defined in the specification. Examples of the compounds include 4-(isopropylamino)-2-((1R,4R)-4-(2,2,2-trifluoroethoxycyclohexylamino)pyrimidine-5-carboxamide and 2-((1R,4S)-4-ethoxycyclohexylamino)-4-((1S,3R)-3-hydroxycyclohexyl-amino)pyrimidine-5-carbonitrile. The compounds are JNK1/JNK2 inhibitors. The compounds may be useful in the treatment of liver fibrotic disorders such as non-alcoholic steatohepatitis, steatosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular carcinoma, or liver fibrosis coincident with chronic or repeated alcohol ingestion, with infection, with liver transplant, or with drug induced liver injury.</p> |